Skip to main content
Home / Current Medicinal Chemistry, Volume 19, Number 7
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Publisher: Bentham Science Publishers

More about this publication?
Volume 19, Number 7, 2012

Articles

Free Content Editorial [ Hot Topic: Targeting Tumor Angiogenesis: An Update (Guest Editor: Girolamo Ranieri)]
pp. 937-937(1)
Author: Ranieri, Girolamo

Favourites:
ADD

Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
pp. 938-944(7)
Authors: Ranieri, G.; Gadaleta-Caldarola, G.; Goffredo, V.; Patruno, R.; Mangia, A.; Rizzo, A.; L. Sciorsci, R.; D. Gadaleta, C.

Favourites:
ADD

mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma
pp. 945-954(10)
Authors: Guarini, A.; Minoia, C.; Giannoccaro, M.; Rana, A.; Iacobazzi, A.; Lapietra, A.; Raimondi, A.; Silvestris, N.; D. Gadaleta, C.; Ranieri, G.

Favourites:
ADD

Inflammation and Antiangiogenesis in Cancer
pp. 955-960(6)
Authors: Ribatti, D.; Crivellato, E.; Vacca, A.

Favourites:
ADD

Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
pp. 961-971(11)
Authors: Sandomenico, C.; Costanzo, R.; Carillio, G.; C. Piccirillo, M.; Montanino, A.; Di Maio, M.; Rocco, G.; Normanno, N.; Perrone, F.; Morabito, A.

Favourites:
ADD

Efficacy and Safety of Bevacizumab in Glioblastomas
pp. 972-981(10)
Authors: De Fazio, S.; Russo, E.; Ammendola, M.; Donato Di Paola, E.; De Sarro, G.

Favourites:
ADD

The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
pp. 982-991(10)
Authors: Rizzo, A.; Spedicato, M.; Mutinati, M.; Minoia, G.; Patruno, R.; Ranieri, G.; L. Sciorsci, R.

Favourites:
ADD

DC-SIGN Antagonists, a Potential New Class of Anti-Infectives
pp. 992-1007(16)
Authors: Anderluh, M.; Jug, G.; Svajger, U.; Obermajer, N.

Favourites:
ADD

Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
pp. 1008-1020(13)
Authors: Bigni, B.; Premi, E.; Pilotto, A.; Padovani, A.; Borroni, B.

Favourites:
ADD

The Development of MetAP-2 Inhibitors in Cancer Treatment
pp. 1021-1035(15)
Authors: Yin, S.-Q.; Wang, J.-J.; Zhang, C.-M.; Liu, Z.-P.

Favourites:
ADD

MMP-2 Selectivity in Hydroxamate-Type Inhibitors
pp. 1036-1064(29)
Authors: Serra, P.; Bruczko, M.; M. Zapico, J.; Puckowska, A.; A. Garcia, M.; Martin-Santamaria, S.; Ramos, A.; de Pascual-Teresa, B.

Favourites:
ADD

Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance
pp. 1065-1075(11)
Author: Nahta, R.

Favourites:
ADD

Gemcitabine: A Critical Nucleoside for Cancer Therapy
pp. 1076-1087(12)
Authors: S. Gesto, D.; M.F.S.A. Cerqueira, N.; A. Fernandes, P.; J. Ramos, M.

Favourites:
ADD

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content